Health Economics›Glioblastoma›Maintenance after first-line therapy

Maintenance after first-line therapy

Glioblastoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Irinotecan and Bevacizumab Variant #01	—	R 19 987	14d	—	—	~2	~R 39 975 indirect	—
Temozolomide and TTFields Variant #01	—	R 8 584	28d	7.1 mo	20.9 mo	5	R 28 206 PFS proxy	2
Temozolomide monotherapy Variant #02	—	R 7 358	14d	4.0 mo	18.8 mo	26	R 129 994 PFS proxy	5

3 of 3 regimens shown